Tilray's International Growth: Market Neglect

Tilray Brands, a cannabis company, has seen its stock price fluctuate significantly over the past five years. In Q3 2022, the company reported a 73% international sales growth, yet the market has largely overlooked this positive development. Tilray has shifted its business model to focus on brand management, with some successful initiatives, but it still faces uncertainty and intense competition. The company's recent acquisition of HelloMD, aimed at expanding its medical cannabis footprint in Canada, has been met with mixed investor sentiment.

The cannabis sector, particularly companies with international exposure and brand management strategies, is affected. Tilray's underperformance has led investors to overlook its international growth, creating a potential buying opportunity. However, the company's uncertain outlook and intense competition may hinder its recovery.

Investors should watch Tilray's fiscal Q4 2022 earnings, expected in late February 2023, for further insights into its growth trajectory. Additionally, regulatory developments in key international markets, such as Germany and the U.S., could significantly impact Tilray's expansion plans and stock performance.